Cerity Partners
NUVB icon

Cerity Partners’s Nuvation Bio NUVB Stock Holding History

Cerity Partners’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$403K Sell
93,963
-2,689
-3% -$15K ﹤0.01% 2415
2025
Q4 		$866K Sell
96,652
-1,231
-1% -$7.63K ﹤0.01% 1791
2025
Q3 		$362K Buy
97,883
+48,065
+96% +$131K ﹤0.01% 2164
2025
Q2 		$97.1K Buy
+49,818
New +$104K ﹤0.01% 2482
2025
Q1 		– Sell
-11,809
Closed -$31.1K – 2573
2024
Q4 		$31.1K Buy
+11,809
New +$30.4K ﹤0.01% 2391

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cerity Partners's NUVB Position: Q1 2026 in Review

Cerity Partners reduced its Nuvation Bio (NUVB) stake by 2.8% in Q1 2026, selling an estimated $15K and leaving 93,963 shares worth $403K. The position accounts for ﹤0.01% of the portfolio, ranked #2415.

Cerity Partners first reported a position in NUVB in Q4 2024 and has held it in 5 quarters since. The position peaked at $866K in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Cerity Partners held 93,963 shares of Nuvation Bio worth $403K as of Q1 2026.
  • Cerity Partners sold 2,689 Nuvation Bio shares in Q1 2026, an estimated $15K.
  • Nuvation Bio made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2415 holding.
  • Cerity Partners first reported a position in Nuvation Bio in Q4 2024 and has held it in 5 quarters since.
  • Cerity Partners's Nuvation Bio position peaked at $866K in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.